Physician profile
Steven E Kamara
NPI 1275640336
$27,082.66
in general payments reported to CMS, 2019-2025
52 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,268 · 2020: $2,970 · 2021: $6,207 · 2022: $3,769 · 2023: $3,289 · 2024: $3,324 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,832 · Education: $32.27 · Travel and Lodging: $5.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,831.66 |
| Education | $32.27 |
| Travel and Lodging | $5.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,362.49 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $3,653.09 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $2,264.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,508.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,446.33 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,213.22 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,177.77 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $1,172.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $830.26 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $592.40 | 2019-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $542.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $527.06 | 2021-2023 | |
| Pfizer INC. | $437.35 | 2019-2024 | |
| Astellas Pharma US INC | $427.61 | 2019-2021 | |
| Allergan, INC. | $422.73 | 2019-2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kamara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.